The proposed treatment is Abraxane and Avastin. This combination is under study in a phase II trial at Northern California Melanoma Center. an open-label, single arm multicenter Phase II study to evaluate the safety and efficacy of the combination of Abraxane and Avastin as first-line therapy for patients with unresectable metastatic malignant melanoma. The patient sample will be approximately 50 individuals, males and females 18 years of age or older with measurable metastatic melanoma.
In regard to Avstin itself, it does not meet Wellpoint policy criteria. It is in trials with a variety of other drugs, such as dacarbazine, interferon and others. The combination of Paraplatin® (carboplatin), Taxol® (paclitaxel), and Avastin® (bevacizumab) is well tolerated and provides clinical benefit in patients with metastatic melanoma, according to the results of a study published in Cancer but it still needs to be confirmed even for that regimen.
Perez DG, Suman VJ, Fitch TR, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. Cancer. 2009; 115: 119-127.